
Celsus Laboratories Inc Profile last edited on: 1/4/07
CAGE:
UEI:
Business Identifier: manufacture heparin anticoagulants Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 01
County: Hamilton
Congr. District: 01
County: Hamilton
Public Profile
Celsus, Inc. manufactures bulk heparins and develops other complex macromolecules belonging to the family of glycosaminoglycans (GAGs). The Company's tradename evokes the name of Aulus Cornelius Celsus, a first-century Roman medical encyclopedist. Celsus Laboratories, Inc., a wholly-owned subsidiary company, is a USDA-approved, FDA-audited drug establishment with the capacity to manufacture and test GAGs used in injectable drugs, blood collection, blood gas analysis, thromboresistant coatings for blood-interacting medical devices, and immobilized GAGs. Celtone, Inc., also a wholly-owned subsidiary, manufactures crude GAGs and protein hydrolysates by a patented process. IntimaX Corporation is an affiliate for the clinical development of the proprietary targeted anticoagulant and heparin cofactor II agonist, Intimatanâ¢
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2003 | 1 | NIH | $223,787 | |
Project Title: New Antiinflammatory Anticoagulant For Cardiac Surgery | ||||
2002 | 1 | NIH | $107,000 | |
Project Title: Non-anticoagulant ODS Heparin in Myocardial Infarction | ||||
2001 | 1 | NIH | $107,000 | |
Project Title: Improved Surgical Anticoagulation Using a HCII Agonist |
Key People / Management
Cornelius L Van Gorp -- President
Alan D Cardin
Alan D Cardin
Company News
There are no news available.